NIH working on information on Celebrex use

	Tweet

The National Institutes of Health said on Friday it was working with the Food and Drug Administration to make sure the public has information “to make informed decisions” about the use of COX-2 inhibitors like Pfizer Inc.’s Celebrex and Merck & Co.’s withdrawn drug Vioxx.

“We are examining the use of these agents in all NIH-sponsored clinical studies. In addition, we are working closely with our colleagues at FDA to ensure that the public has the information they need to make informed decisions about the use of this class of drug,” NIH Director Elias Zerhouni said in a statement.

Meanwhile, acting FDA Commissioner Lester Crawford said on Friday that the agency has “great concerns” about Celebrex and other COX-2 inhibitors.

The FDA is “keeping all options open” on Celebrex, including the possibility of adding a black box warning about safety risks. Crawford said he expected to have more announcements about Celebrex in the next few days.

------------------------
CELEBREX © is a recent break through in the treatment of osteoarthritis and rheumatioid arthritis.Celebrex ® is being hailed by many as a miracle drug. Celebrex enables people to live more active lives, not limited by arthritis pain.

Order CELEBREX online !

RELATED STORIES:
Consumer ads pump up prescription drug costs   US scientist defends ‘morning-after’ pill decision   Drugs must have warnings on suicide   Canadian study slams costly “me-too” medicines   Novartis diabetes drug effective in combo study   Drug firms offer saving card for U.S. uninsured   New flu strain picked for flu vaccine mix   Tamiflu could halve pandemic flu death toll   Expert Warns of Overuse of Over-the-Counter Pain Medication   Antibiotics sold illegally in Hispanic NYC stores   New Guidelines for Prescribing Opioid Pain Drugs Published   Don’t compromise safety, says drug import report

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]